Compare Essex Property Trust, Inc. (ESS) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Cassava Sciences Inc — how do they compare? Essex Property Trust, Inc. trades at $269.13 (market cap $17.26B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Essex Property Trust, Inc. is far larger — about 438.1× Cassava Sciences Inc's market cap, and Essex Property Trust, Inc. pays a 3.86% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Essex Property Trust, Inc. for 111 Days and Cassava Sciences Inc for 37 Days on average.
| ESS | FLNA | |
|---|---|---|
Market Cap | $17.26B | $39.40M |
Volume | 454,464 | 759,018 |
Sector | Real Estate | Health |
52-Week High | $298.33 | $4.64 |
52-Week Low | $239.61 | $0.68 |
Typical Hold Time | 111 Days | 37 Days |
Enterprise Value | $23.86B | -$43.28M |
Dividend Yield | 3.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $268.05, down 1.63% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly earnings, missing in Q4 2025 and Q2 2026 but beating in Q1 2026, with Q3 2026 results pending. Revenue reached $1.89B in 2025, with a net income margin of 21.48%, while valuation ratios like a P/E of 41.83 suggest a premium. Recent news highlights strong Q2 2026 results, raised guidance, and a declared dividend of $2.59 per share.
The outlook is cautiously optimistic, supported by operational strength and resolved litigation, but high valuation and earnings volatility pose risks. Analyst consensus is a Buy with a $303.41 price target, indicating potential upside, though investors should monitor debt levels and consistent earnings delivery against expectations.
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
